Actively Recruiting
Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer
Led by Minia University · Updated on 2025-05-18
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial aimed to determine whether neoadjuvant chemoradiotherapy improves overall survival compared with upfront surgery, both followed by adjuvant chemotherapy in patients with resectable and borderline resectable pancreatic cancer.
CONDITIONS
Official Title
Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Computed tomography (CT) with pancreatic protocol and vascular mapping
- Histopathologically proven malignant tumor by CT-guided or endoscopic ultrasound (EUS)-guided biopsy
- Resectable pancreatic cancer defined by no tumor contact with the Superior mesenteric artery, Celiac axis, and Common hepatic artery, and tumor contact with the superior mesenteric vein or portal vein 90 degrees or less
You will not qualify if you...
- Borderline resectable and locally advanced pancreatic cancer
- Tumor located at the tail of the pancreas
- Metastatic pancreatic cancer
- Patients unfit for surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Minia University
Minya, Egypt, 61611
Actively Recruiting
Research Team
A
Abdelrahman M Salah, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here